Member Info for CHELSEA7

""Why Sclp are getting It hard to get Interest from a large Pharma""

Well that is a statement of fact, which I have a problem with. How do we know there has been no interest at all?? I think we can presume there hasn"t been an offer anywhere near the value Scancell would agree too, hence the emphasis on data and in SCIB1s case more data from a combination setting with a CI, as is Keytruda. We only get to hear the whole story as and when deals are finalised, not as a daily diary of events.

There was even a ""deal muted" some years ago, which never transpired, and wasn"t it Scancell themselves who advised us they were targetting for partnerships large companies, like Biontech and presumably like our collaboration with the third platform, to take us through trials to ensure we do get best value for shareholders?? I think we can presume from Vulpes Investment that there is where they see our potential too.

Bermuda,

Just out of interest if Keith Flaherty would have been PI for both arms UK and USA , why was it not possible just to be PI of the UK arm?? Just curious.

Buys 21.5k

Sells 20k

Wonder whether we will get an RNS tomorrow about the abstracts?? And five weeks now since the first patient was enrolled for trial (Aug 19th)

Thanks for the info about the abstracts Bermuda, and I had forgotten about Keith Flaherty, who would have been Principal Investigator in the U.S.A arm, think we can presume his enthusiasm never dwindled. Night guys.

Taking up to 70k at 6.877, over that 8.765

Wasn"t it Keith Flaherty who commented also that SCIB1 data was well beyond the current norms????

Lets not forget there have been a couple of thousand combo trials launced in the last 4/5 years. One heck of a data base to compare our data with and there are a few hundred triple combination trials taking place too.

"" Sadly looking like Sclp ScIB1 needs combos"", not IMHO, Keytruda is not approved in all cancer types and if we could improve on the data that Keytruda has as a monotherapy then we are all winners. SCIB 1 has never failed a trial, this is a tremendous opportunity for Immunobody to make a case for Phase 3 trials also.

Mind you, it does show as with the collaboration on the third platform we are knocking on a few right doors, lets hope the journies are fruitful.

I don"t think anything WTP, I think Bermudas 13.31 says it all really.

Probably an impossible question Bermuda, I asked the same last week, but given the early stage of its pipeline, how do they value such an IPO?

Oh well Tom Watson has been silenced!!!

All very quiet, Wins move up to 7.5, but stay on the bid with three others at 6.8p, hence blue.

One heck of a spread, indicitive or not, but that is one heck of a lot of work that has gone into those abstracts. GL Scancell at the Conference.

Hmmm.............

https://www.businessinsider.com/eli-lilly-to-buy-loxo-oncology-in-8-billion-cancer-drug-deal-2019-1?r=US&IR=T

Morning guys, thanks for the info

Crackin, was that your buy, buddy?

Night

At 7.15

Yeah, just the 1629

Over 215k+ 6.851..................trades coming...............!!

Odds on favourite. More to come trade wise though.

Latest Trades
Date & Time Volume Price
23/09/2019 13:09 200,000 7.015
23/09/2019 13:09 200,000 7

Up to 110k now 6.8355, and over 215k 6.825

Up to 50k 6.8355 and over still 6.825, Creeping up IMHO buyer about.